Skip to main content
. 2017 Sep 26;7(17):4340–4349. doi: 10.7150/thno.18563

Figure 2.

Figure 2

In vitro analysis of different PARP inhibitors on W780 and W0069 breast cancer cell lines derived from Brca1Co/Co;MMTV-Cre;p53+/- mice. Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in A) W780 B) W0069 cells. C) Measured dose response curve and IC50 of Talazoparib in W780 and W0069 cells.